Insulet Corporation
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes. Its core business is replacing multiple daily injections and traditional tubed pumps with wearable, disposable pod-based insulin delivery, supported by training, customer support, reimbursement, and billing services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueTubeless wearable insulin delivery platforms, including Omnipod 5 and Omnipod DASH.
Recurring disposable pods and related supplies used with the Omnipod platform.
Pods sold to Amgen for use in the Neulasta Onpro delivery kit.
Products
Reported · share of revenue- U.S.Omnipod70.9 %
- International Omnipod27.9 %
- Drug Delivery1.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Insulet sells primarily to people with insulin-dependent diabetes, with demand driven by patients transitioning from multiple daily injections or older pump systems to Omnipod. It also serves payors, distributors, clinicians, and pharmacies that influence access, reimbursement, onboarding, and ongoing adherence. A smaller customer base consists of Amgen for drug-delivery pods used in the Neulasta Onpro kit.
Buy Omnipod 5 or Omnipod DASH to replace injections or tubed pumps and improve convenience.
Influence access and reimbursement by evaluating the clinical and economic value of Omnipod.
Buys and fulfills recurring pod orders, supporting scale and patient retention.
Support adoption through training, onboarding, and patient education.
Buys pods for the Neulasta Onpro kit, a small non-diabetes revenue stream.
Strategy
Insulet is focused on expanding Omnipod adoption, especially through Omnipod 5 conversions and new customer acquisition in the U.S. and abroad. It is also investing in manufacturing capacity, supply-chain resilience, and cloud-based capabilities to support growth, improve service, and scale globally.
Recurring pod revenue depends on adding users and converting existing patients to the latest platform.
Growth requires enough capacity, quality control, and logistics to meet demand without service disruptions.
Retention is critical because most revenue comes from recurring pod usage after initial adoption.
Geography
Insulet generated most revenue in the United States, with international markets contributing a meaningful and fast-growing share. Management highlighted launches and rollouts of Omnipod 5 in Australia, Canada, the Nordics, France, and additional markets, while manufacturing expansion includes Costa Rica and Malaysia. The business is exposed to currency, trade, and supply-chain risks because it relies on international suppliers, a contract manufacturer in China, and overseas manufacturing capacity.
Risks
Insulet is highly dependent on the Omnipod platform, so any product performance issue, competitive loss, or reimbursement setback could materially affect revenue. Growth also increases operational complexity across manufacturing, logistics, and international expansion, while IT and cybersecurity risks matter because the company handles sensitive medical and financial data. Foreign exchange, trade, supplier concentration, and leadership transitions add further execution risk.
- Dependence on Omnipod platformImpact: CriticalLikelihood: Medium
Nearly all revenue comes from one product family, so any slowdown in adoption or retention would directly reduce sales.
Exposure: Omnipod 5 and Omnipod DASH
- Competitive pressure in diabetes devicesImpact: HighLikelihood: Medium
The company competes with MDI therapy, smart pens, tubed pumps, and emerging patch pumps.
Exposure: Patient acquisition and retention
- Supply chain and manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on outside vendors, overseas suppliers, and manufacturing sites in multiple countries.
Exposure - Cybersecurity and IT systems failureImpact: HighLikelihood: Medium
Systems process sensitive medical, financial, and customer data and support core operations.
Exposure: Cloud-hosted enterprise systems and third-party vendors
- International and foreign exchange exposureImpact: MediumLikelihood: Medium
A growing share of revenue comes from outside the U.S., creating currency and regulatory exposure.
Exposure: International Omnipod markets
Accounting
Judgemental itemsRecurring pod sales, pharmacy channel arrangements, and related-party sales affect timing and net revenue.
Impact: Revenue and gross margin
Rebate estimates reduce reported revenue and depend on utilization and payer mix.
Impact: Net sales
Quality, demand, and product performance assumptions affect reserve levels.
Impact: Cost of revenue and operating profit
International growth and changing tax laws create judgment in tax provisions and disclosures.
Impact: Tax expense and effective tax rate
Cloud-based capabilities and plant expansion require capitalization and later depreciation/amortization.
Impact: Operating expenses, depreciation, and cash flow
Similar listed companies
Publicly listed companies with a comparable business focus.
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
InfuSystem Holdings, Inc
INFU · Surgical & Medical Instruments & Apparatus
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Embecta Corp.
EMBC · Surgical & Medical Instruments & Apparatus
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Omnicell, Inc
OMCL · Electronic Computers
Last updated: 24/09/2026